Download image:

Elizabeth B. Andrews

Vice President, Pharmacoepidemiology and Risk Management, RTI-HS

Elizabeth Andrews, PhD, is the vice president of Pharmacoepidemiology and Risk Management at RTI Health Solutions. Dr. Andrews provides consultation for pharmaceutical companies and the U.S. Food and Drug Administration on therapeutic risk management and pharmacoepidemiology, and she directs research programs that evaluate drug safety and compliance with prescribing and treatment guidelines. She oversees the conduct of large, prospective patient registries, web-based surveys, and studies using large existing databases. Dr. Andrews has worked extensively in the areas of HIV and sexually transmitted diseases, birth defects and neonatal health, asthma and chronic obstructive pulmonary disease, and irritable bowel syndrome. She is a fellow and past president of the International Society for Pharmacoepidemiology, and coeditor of Pharmacovigilance. She is an adjunct associate professor of the University of North Carolina School of Public Health and School of Pharmacy, and a member of the Steering Committee for the Innovation in Medical Evidence Development and Surveillance (IMEDS) Program of the Reagan Udall Foundation for the FDA.


PhD, Epidemiology, University of North Carolina at Chapel Hill; MPH, Health Policy and Administration, University of North Carolina at Chapel Hill.

Latest Publications

Andrews, E.B., Gilsenan, A.W., Midkiff, K.D., & Harris, D.H. (2015). Comments on Bang et al.: The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporosis International, 26 (5):1663-1664.
Matharu, M., Pascual, J., Nilsson Remahl, L., Straube, A., Johannes, C., Odom, D., Gutierrez, L., Andrews, E., et al. (2015). Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union, Cephalalgia, 35 (6, Suppl.):39-39.
Tennis, P., Chan, K.A., Curkendall, S.M., Li, K., Mines, D., Peterson, C., Andrews, E.B., Calingaert, B., Chen, H.Y., Deshpande, G., Everage, N., Holick, C.N., Meyer, N.M., Nkhoma, E.T., Quinn, S., Rothman, K.J., et al. (2015). Topiramate use during pregnancy and major congenital malformations in multiple populations. Birth Defects Research Part A: Clinical and Molecular Teratology, 103 (4):269-275.
Namazy, J.A., Rahmaoui, A., Cabana, M.D., Scheuerle, A.E., Thorp, J.M., Carrigan, G., & Andrews, E.B. (2015). Perinatal outcomes in pregnant women exposed to omalizumab: Interim results from a prospective, observational study, Journal of Allergy and Clinical Immunology, 135 (2, Suppl):AB1.
Namazy, J., Cabana, M.D., Scheuerle, A.E., Thorp, J.M., Chen, H., Carrigan, G., Wang, Y., Veith, J., & Andrews, E.B. (2015). The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy. Journal of Allergy and Clinical Immunology, 135 (2):407-412.
View all publications by Elizabeth B. Andrews (135)


  • Drug Safety
  • Therapeutic Risk Management
  • Therapeutic Outcomes and Safety